Effectiveness of an organized colorectal cancer screening program on increasing adherence in asymptomatic average-risk Canadians by Thomas J Charters et al.
Charters et al. BMC Health Services Research 2013, 13:449
http://www.biomedcentral.com/1472-6963/13/449RESEARCH ARTICLE Open AccessEffectiveness of an organized colorectal cancer
screening program on increasing adherence in
asymptomatic average-risk Canadians
Thomas J Charters1*, Erin C Strumpf2,3 and Maida J Sewitch4,5Abstract
Background: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and second highest cause of
cancer-related mortality in Canada. Despite the availability of screening services and establishment of guidelines,
utilization of colorectal cancer screening in Canada remains low. In 2008, the province of Ontario launched
ColonCancerCheck, an organized colorectal cancer screening program aimed at increasing CRC screening
adherence. In this study, we adopt a quasi-experimental approach to estimate and describe the impact of
ColonCancerCheck on screening behavior in the asymptomatic average risk population.
Methods: Annual screening rates from the target population were estimated using five cycles of the Canadian
Community Health Survey, a cross-sectional nationally representative survey of health status, healthcare use, and
determinants of health in the Canadian population. We used a difference-in-differences design to measure the
overall impact of ColonCancerCheck on past-year fecal occult blood testing (FOBT) and endoscopy in Ontario
relative to the rest of Canada. Several verification tests validated the suitability of our model specification.
Results: The difference-in-differences analysis shows that ColonCancerCheck increased FOBT screening in the
average risk population by 5.2 percentage points (95% CI [3.2, 7.2]), an increase of 33% relative to pre-program
screening rates. The program had no observed effect on endoscopy screening and we found no evidence that
ColonCancerCheck differentially altered the screening practices of population sub-groups.
Conclusions: Our findings suggest ColonCancerCheck has been successful at increasing use of FOBT in the
asymptomatic average risk population.
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Colorectal cancer (CRC) constitutes the second highest
cause of cancer mortality and third most commonly
diagnosed cancer in Canada [1]. In 2013, the incidence
of CRC in Canada is projected to be 60 per 100,000 in
males and 40 per 100,000 in females, with approximately
4200 women and 5000 men dying from it [1]. The
demographic shift towards an older population has in-
creased CRC incidence and mortality over the last thirty
years [2]. Despite opportunities for early detection [2],* Correspondence: thomas.charters@mcgill.ca
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reproduction in any medium, provided the orCRC tends to be diagnosed at advanced cancer stages [3],
which are associated with both lower probabilities of sur-
vival [4] and greater costs to the healthcare system [5].
CRC screening guidelines have been developed and
adapted based on the recognition that early detection
and treatment can significantly reduce CRC morbidity
and mortality [6]. These guidelines were based on exist-
ing knowledge of the best means for early detection of
cancer [7-9] (since updated [10]) with screening recom-
mendations typically calling for annual or biennial
screening by a noninvasive stool-based test such as a
fecal occult blood test (FOBT) with follow-up with
endoscopic tests such as flexible sigmoidoscopy or col-
onoscopy. A Cochrane systematic review of several largel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing strategies incorporating biennial fecal occult blood
tests estimated that screening reduces CRC mortality by
15% [11]. Population-based screening is generally thought
to be cost effective [12,13] and is supported by Canadian
[14,15] and other [16] microsimulation models.
Screening rates for CRC in Canada remain quite low
despite the presence of screening guidelines, evidence of
screening effectiveness, and universal health insurance
coverage for these procedures [17]. In 2003, adherence
to screening guidelines for FOBTs among average risk,
target-age individuals was only 15% [18], increasing to
23% in 2008 [19]. Screening rates have also been ob-
served to vary by province, with Ontario historically hav-
ing higher rates than much of the rest of Canada [19].
By contrast, 73% of Canadian women aged 50–69 re-
ported mammogram adherence in this time period [20].
Evidence suggests that both Canadian patients [21] and
physicians [21,22] were unknowledgeable of, or non-
adherent to, recommended screening protocols for CRC.
Outside of Ontario and in Ontario prior to 2008, CRC
screening broadly followed the procedures as outlined in
the national guidelines [7-9], albeit in an opportunistic
or individualistic manner which gave rise to concerns of
underutilized or inappropriate screening and lack of
quality assurance [23].
In order to address low adherence to screening guide-
lines, Ontario’s Ministry of Health and Long Term Care
launched an organized population-based colorectal can-
cer screening program called ColonCancerCheck in
March of 2008 [23]. ColonCancerCheck targeted adults
ages 50 and older with the goals of reducing CRC mor-
tality and enhancing the involvement of physicians in
patient screening. The program utilized existing screen-
ing recommendations for biennial FOB testing with
endoscopy follow-up for average risk adults with colon-
oscopy being recommended for those of high risk. It also
introduced outreach and organizational frameworks
designed to increase screening adherence and educate
both the public and health care providers about proper
screening protocols.
To increase adherence to screening practices in the
target population, ColonCancerCheck directed educa-
tional media campaigns to physicians through informa-
tion kits and counseling manuals, and to the public,
through television, websites, posters, pamphlets, and
street teams at public events. With primary care pro-
viders (PCPs) taking the central role of distributing kits
and following up with patients, arrangements were made
for those without PCPs to obtain kits through pharma-
cies or through calling a 1–800 number. Contracts were
established with laboratories to process tests and de-
velop quality-control standards. A single brand of FOBT
kit with sufficient accuracy and modest dietary restric-tions was selected and used by all participating labora-
tories to help ensure quality, consistency, and interpre-
tability of results. FOBT kits were handed out with
instructions and post-paid envelopes to be completed at
home and mailed to central laboratories for processing.
An organizational framework was developed for screen-
ing invitations and results letters with pilot programs for
invitation-based outreach in development. PCPs would
be informed of their patient’s test results and follow-
through by arranging colonoscopies if positive, with
negative results leading to notification and recall for
testing in two years. Incomplete and unreadable tests
would be corrected with instructions returned for re-
tests [23]. Prior to the launch of the program, FOBT kits
were sent out to over 10,000 physician and nurse practi-
tioner offices and 3000 pharmacies [23].
Some evidence suggests increased screening in Ontario
after the program’s introduction. Health insurance claims
indicate that 30% of Ontarians aged 50–74 had at least one
complete FOBT in the previous two years in 2007–8
(inclusive) compared to 20% in 2005–6 [23]. Survey data
corroborates this, suggesting FOBT adherence rose from
21% to 31% from 2005 to 2008, while endoscopy test ad-
herence rose from 24% in 2005 to 30% in 2008, in those 50
and older [19]. However, these findings are insufficient to
draw conclusions concerning the impact of ColonCan-
cerCheck since there was a general trend of increased
screening across Canada with increases observed in several
provinces without screening programs during this time
period [19]. Similarly designed programs were under vari-
ous stages of development in Manitoba [24] and Alberta
[25] during this time, with Manitoba instigating a pilot pro-
gram for CRC screening in two health regions. However,
no province-wide CRC screening programs outside of
Ontario were implemented during the study period.
The purpose of the present study was to measure and
describe the impact of ColonCancerCheck on CRC
screening in the asymptomatic, average risk population
in Ontario. We used a quasi-experimental design and a
difference-in-differences model, which measures the
change in screening rates in Ontario relative to the
change in the rest of Canada. This model has been used
extensively to measure the impacts of health care pol-
icies, including the effects of public reporting of hospital
performance on mortality [26] and the effects of an in-
tensified diabetes management program [27]. A similar
model was also used to measure the effects of mandated
insurance coverage for endoscopy screening in the U.S.
on CRC screening rates among adults aged 50–64 [28].
Methods
Data
This study used the confidential microdata files from the
Canadian Community Health Survey (CCHS) in 2003,
Table 1 Participation in module on CRC screening
questions by year
Province 2003 2005 2007 2008 2009
Newfoundland and Labrador ●→ ●→ ●→ ●→ ●→
Prince Edward Island ●→ ●→ ●→ ●→
Nova Scotia ●→ ●→ ●→
New Brunswick ●→ ●→ ●→
Quebec ●→
Ontario ○→ ●→ ●→ ●→ ●→
Manitoba ●→
Saskatchewan ○→ ●→ ●→ ●→
Alberta ●→
British Columbia ●→ ●→
An open circle indicates not all health regions were surveyed for this province;
a closed circle indicates all health regions were surveyed. We found no
evidence of disproportional representation of health regions which would
influence the screening outcome measures, so the subsample of health
regions used in the 2003 cycle was thought to be a suitable representative of
the province.
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Canada Research Data Centres. The CCHS is a cross-
sectional, nationally representative survey of individuals
aged 12 and older living in private dwellings in Canadian
provinces and territories. Persons living on Indian re-
serves, on Crown lands, in institutions, in remote re-
gions, or serving in the Canadian Forces, are excluded
from the sample frame [29]. The CCHS was initially a
biennial survey although was revised in 2007 to become
an annual survey with smaller samples. During the study
period, the sample size ranged from 61,679 in 2009 to
135,573 in 2003 with response rates ranging from 73.2%
in 2009 to 80.7% in 2003.
The primary outcome in this study was CRC screening
in the past year, which was assessed based on questions
pertaining to FOBT and endoscopy tests and time since
their receipt. Respondents were coded as having been
screened for CRC in the past year if they reported re-
ceiving FOBT and/or endoscopy “less than one year
ago”. FOBT and endoscopy were described by the CCHS
to interviewees as follows: “An FOBT is a test to check
for blood in your stool, where you have a bowel
movement and use a stick to smear a small sample on a
special card” and endoscopy: “A colonoscopy or sig-
moidoscopy is when a tube is inserted into the rectum
to view the bowel for early signs of cancer and other
health problems” [30]. During the study period, the
Canadian screening guidelines were consistent with re-
spect to FOBT and endoscopy use. Past-year receipt of
screening was used in order to minimize measurement
error and exposure misclassification. The independent
variable was exposure to ColonCancerCheck. Exposed in-
dividuals were CCHS respondents residing in Ontario in
2008 and 2009, while unexposed individuals lived in
Ontario in 2003, 2005, and 2007 or in another province
in any survey year. Details on socio-demographic charac-
teristics, health status, and the medical services use of
respondents were included as potential confounders.
This study is a secondary analysis of data collected by
Statistics Canada. The CCHS, which operates under the
provisions of the Statistics Act. 1970-71-72. C.15, s.1
[31], safeguards release of information which could
disclose the identity of any person or organization and
obtains informed consent from interviewees with per-
mission granted from parents/guardians for youth inter-
viewees [29]. As a secondary analysis of anonymous
data, our study falls under Article 2.4 of the Canadian
Tri Council Policy Statement on Ethical Conduct for
Research Involving Humans: “REB review is not required
for research that relies exclusively on secondary use of
anonymous information, or anonymous human bio-
logical materials, so long as the process of data linkage
or recording or dissemination of results does not gener-
ate identifiable information” [32]. Because the databasedoes not contain identifiable information, the McGill
University Faculty of Medicine Institutional Review
Board did not require ethics review and approval. This
study was approved by the Social Sciences and Human-
ities Research Council of Canada on March 23, 2011
(Project 11-SSH-MCG-2659).
Population
We sought to approximate the principal target popula-
tion of ColonCancerCheck [23] of asymptomatic, aver-
age-risk adults aged 50–74. We removed identifiable
high risk respondents from the sample including those
who reported screening with either FOBT or endoscopy
due to family history of CRC, or as a follow-up to treat-
ment of CRC. Those reporting bowel disease such as
colitis or Crohn’s disease were also excluded. We ex-
cluded respondents living in Canadian territories from
the control group, as the geographically remote territor-
ies have limited comparability to Ontario and were
noted by others [19] to yield unreliable screening esti-
mates. While Ontario and Newfoundland and Labrador
were included in every survey year, the control group
consisted of an unbalanced panel of provinces since
CRC screening was an optional module in which most
provinces participated only in selected survey years
(Table 1).
Analysis
We combined five cycles of the CCHS to assess tem-
poral trends in screening by province. Given consistency
in the form and type of questions, sampling frames, and
population of interest over time, pooling across years
was felt to be appropriate. To assess whether the
other provinces were an appropriate control group for
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covariates in Ontario and other Canadian provinces in
the pre-policy period. To estimate the effect of Colon-
CancerCheck on screening activities we employed the
difference-in-differences (DD) model. The DD’s quasi-
experimental framework takes the form of a fixed effects
model suited to measuring the impact of a policy which
varies at a group (provincial) level over time in a non-
randomized setting [33]. The DD design is attractive as
it removes bias due to temporal trends in screening,
from confounders common to both the intervention and
control groups and due to time-invariant differences be-
tween Ontario and other Canadian provinces.
We ran the following logistic regression:
Y igt ¼ β0þ β1  Ontariog þ β2  Post Interventiont
þ β3  Ontario  Postgt þ β4  covarigt þ εigt
Where Y is receipt of screening in the past year for in-
dividual i in province group g and time t. β3 is the effect
measure, representing the change in screening rates due
to ColonCancerCheck (CCC) relative to the change in
screening in provinces without the organized screening
program. Indicator variables for the treatment group
(Ontario) and for the post-intervention period (2008–
09) serve as controls and adjust for fixed differences be-
tween the intervention and control provinces, and com-
mon trends over time, respectively. Covariates included
indicators for each survey year and province, sex, age
category (50–64, 65–74), geography (rural, urban loca-
tion), self-rated health (poor, fair, good, very good, excel-
lent), having a regular physician, ever having had a flu
shot, a physical activity index score aggregating a num-
ber of leisure activities (active, moderately active, in-
active), smoking status (regular, occasional, never),
ethnicity (Caucasian, other), education (<secondary
school, secondary school, some post-secondary, post-
secondary), income (household quintiles standardized to
national level), and the number of reported visits to a
general practitioner in the past year (0–3, 4–10, 11–19,
20 or more). Further details on question methodology
and operationalization may be found elsewhere [30,34].
Because the DD design examines relative changes over
time, it requires that trends in screening, rather than
levels of screening, be similar in the pre-intervention
period. Therefore, under the assumption of parallel
pre-intervention screening trends, two provinces with
differing levels of screening prevalence are comparable.
Having chosen an appropriate control group with similar
pre-intervention trends and baseline characteristics, we
interpret the intervention as being responsible for any
deviation from these previously established trends [33].
To our knowledge, there were no program or budgetary
actions initiated at the provincial level during the studytime period which would have substantially impacted
CRC screening rates other than ColonCancerCheck, and
we therefore feel this assumption is valid.
We conducted a complete case analysis. Secondary
analysis suggested that item non-response was not in-
formative of the outcomes. All results were translated
from logistic regression coefficients into predicted prob-
abilities, and marginal effects were calculated on the risk
difference scale with 95% confidence intervals. Using an
approach recommended for the CCHS [35], we rescaled
the original sample weights to account for differences in
sample size across years by a factor of nj/(n1 + n2 +…nj)
where n represents the sample size of each survey 1,2…j
[36]. The CCHS has a complex design including stratifi-
cation, multiple stages of selection, and unequal selec-
tion probabilities [29]; therefore, bootstrap repeated
replications [37] with pooling-adjusted weights were
used to calculate variance estimates. All statistical ana-
lyses were performed using STATA version 11 [38].
Model verification
We also performed three tests to verify the suitability of
the DD model. The first was an extension of the DD
model known as a difference-in-difference-in-differences
model (DDD) which tests for the existence of factors
that differentially affect screening rates in Ontario in the
post-intervention period which could mistakenly be at-
tributed as impacts of the ColonCancerCheck program.
This analysis adds a further interaction to the β3 term
with several variables separately, noted previously [19] to
be important modifiers of screening practices. These in-
cluded having a regular doctor, being aged 65–74 years
old, being “inactive”, reporting ever having had a flu
shot, and being aged 35–49, this last category being less
likely to screen. The DDD design has previously been
used connecting variations in states’ introduction of the
Medicaid program and labor force participation of
eligible women [39]. Second, we conducted a DD falsifi-
cation analysis using pre-CCC survey years with 2007 as
the simulated post-intervention period. Under this test,
a significant result would indicate the presence of re-
sidual confounding attributable to nonparallel trends be-
tween groups. Third, we used an alternative dependent
variable, “ever having had a flu shot”, to check for bias
plausibly linked to unmeasured changes between study
groups through expansions to new users of flu vaccines.
Since ColonCancerCheck should have no impact on use
of flu shots, a significant result would suggest that the
DD estimate is driven by larger systematic changes be-
tween health care systems within Canada.
Results
The total sample based on province-years that adminis-
tered the CRC screening module was 81,262, which was
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screening due to family history, CRC treatment, or hav-
ing colitis (10,030) and restricting the data for complete
case analysis (13,090). Ontario contributed 19,888 and
11,293 observations and the control provinces 12,324Table 2 Comparisons of study population in Ontario and othe





50-64 74.0 73.2 Country of birth
65-74 26.0 26.8 0.159 Canada
Sex Time in Canada since im
Male 53.0 52.0 0.136 Non-Immigrant
Female 47.0 48.0 20 or more
10 to 19
Marital status 0 to 9
Married 74.3 73.0 0.067
Common-Law 4.1 4.7 0.082 Health s
Widowed 6.6 6.6 0.848
Separated 2.6 2.7 0.560 Self-perceived Health
Divorced 7.3 7.6 0.395 Poor
Single, Never Married 5.2 5.4 0.614 Fair
Good
Highest level of education Very Good
< Secondary School 24.9 20.0 0.000 Excellent
Secondary School 17.3 18.2 0.181
Some Post-Secondary 6.2 6.2 0.966
Post-Secondary 51.7 55.6 0.000 Body mass index
Underweight
Household incomea Overweight
Quintile 1 (Lowest) 19.9 16.0 0.000 Obese-Class I
Quintile 2 20.0 18.4 0.029 Obese-Class II
Quintile 3 19.6 19.7 0.902 Obese-Class III
Quintile 4 18.9 20.1 0.080
Quintile 5 (highest) 21.7 25.8 0.000 Health beh
Geography Type of smoker
Urban 69.1 82.8 0.000 Daily
Rural 30.9 17.2 Occasional
Never
N=30,484; Weighted N=1,468,619; All proportions weighted. aBased on national comand 14,637 observations in the pre- and post-interven-
tion periods, respectively.
Comparisons between the intervention and control
groups in the pre-intervention period generally show
similarities across a range of measures, indicating ther Canadian provinces (Control) 2003-2007
ontrol Ontario p Control Ontario p
Leisure physical activity
91.5 85.5 0.000 Active 23.5 22.8 0.322
8.5 14.5 Moderately Active 26.8 26.8 0.995
Inactive 49.6 50.4 0.400
81.6 65.4 0.000 Heavy drinkingb
Never 74.4 74.7 0.657
migration <Once a Month 14.1 13.9 0.654
68.1 61.9 0.000 Once a Month 4.0 3.8 0.601
26.0 30.7 0.000 2-3 Times a Month 2.6 2.8 0.440
3.2 4.8 0.001 Once a Week 3.1 2.6 0.058
2.7 2.6 0.899 > Once a Week 1.8 2.2 0.058
tatus Health care use
Has regular MD
3.6 3.7 0.730 Yes 93.3 94.4 0.007
11.7 11.4 0.593
30.2 29.8 0.592 Screening in past year:
FOBT
36.3 35.9 0.581 Yes 8.4 13.5 0.000
18.2 19.3 0.109
Screening in past year: endoscopy
Yes 3.3 6.0 0.000
1.0 1.1 0.442 Ever had a flu shot
41.0 41.1 0.831 Yes 52.7 70.7 0.000
15.7 15.5 0.709
3.7 3.5 0.706 No. GP consultations
past year
1.5 1.5 0.919 0 to 3 62.3 65.7 0.000
4 to 10 30.4 28.9 0.062
aviours 11 to 19 5.8 4.4 0.000
20 or more 1.6 1.0 0.005
15.5 15.6 0.883 Year
2.7 3.0 0.397 2003 60.2 15.3 0.000
81.8 81.4 0.603 2005 30.2 53.6 0.000
2007 9.6 31.1 0.000
position excluding territories. bImbibing five or more drinks on one occasion.
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ences include urban geography, ethnic diversity, flu shot
uptake, and screening adherence (Table 2). Figure 1 indi-
cates FOBT screening trends in Ontario rose more con-
sistently than those in the control group, and jumped
from 15.7% to 21.9% from 2007 to 2008. FOB testing
trends in the control group are fairly similar to those in
Ontario overall, despite an uncharacteristic decrease in
2005. FOBT use in the control group decreases from
12.4% in 2007 to 10.6% in 2008. Rates of past year en-
doscopy screening rose gradually in both groups, with
little indication of a change in trajectory in 2008.
Table 3 shows the results of the difference-
in-differences regressions. We estimate a 5.2 [3.2, 7.1]
absolute percentage point increase in the proportion of
asymptomatic average risk individuals screened with
FOBT in the past year due to ColonCancerCheck. This
effect represents a significant marginal increase over
significant temporal trends in FOBT screening and sig-
nificant differences in screening between provinces, as
indicated by the time and group coefficients, respect-
ively. There were no effects found using this model
pertaining to endoscopy outcomes 0.9 [−0.5, 2.3].
The difference-in-difference-in-differences analysis al-
lows us to test for effect measure modification to de-
scribe the impact of ColonCancerCheck and investigate
whether it may alter the screening practices of popula-
tion sub-groups. No evidence was found suggesting this
is the case, or that the results are biased by any unmeas-
ured underlying sample characteristics (Table 4). A
near-significant change in association was related to
endoscopic procedures and having a regular medical
doctor in post-intervention Ontario, indicating a 6.0
[−0.7, 13.7] point marginal effect. However, this change













CCHS Cycles 2.1, 3.1, 2007, 2008, 2009
Figure 1 Past Year CRC Screening in Canada.services and may relate to changes in mode of services
delivery. Tables 5 and 6 indicate that the placebo tests
did not find evidence of bias as evidenced by a lack of
significant results for the Ontario*Post interaction term.
Discussion
We used a quasi-experimental causal approach to meas-
ure the effect of ColonCancerCheck on the past-year
screening behavior of asymptomatic average risk adults
ages 50–74. We found evidence that ColonCancerCheck
increased screening adherence within the time frame
studied. Past-year screening rates using FOBT increased
by an absolute 5.16 [3.19, 7.12] percentage points,
equivalent to a 33% increase relative to screening rates
in Ontario in 2007. Our findings were robust to different
model specifications. Additionally, we failed to find any
evidence that past-year endoscopy screening rates were
affected by the program. Subsequent tests of model suit-
ability did not indicate evidence of effect modification by
any of the factors investigated, or sources of bias. Differ-
ences in demographic and medical characteristics be-
tween the intervention and control groups were minor
and accounted for by the DD model which controls for
time-invariant differences across groups. Bias may result
if underlying variables were to change alongside the
intervention, although inter-group analyses and DDD
models did not find any evidence of such interactions.
Although there has been some evidence for increases
in FOBT use in Ontario in 2008 [19,23], this study is the
first to estimate the proportion of these increases which
can plausibly be attributed to ColonCancerCheck. To our
knowledge, this is also the first study to analyze the dir-
ect impact of a CRC screening program using a quasi-
experimental model. It is unsurprising that a program





Table 3 Difference-in-differences estimates for fecal occult blood test and endoscopy outcomes
Outcome DDa DDb
Marginal effect 95% CI p Marginal effect 95% CI p
FOBT Post intervention 0.073 0.052 0.095 0.000 0.074 0.053 0.095 0.000
Ontario 0.082 0.059 0.104 0.000 0.064 0.041 0.086 0.000
Ontario*Post 0.050 0.030 0.070 0.000 0.052 0.032 0.071 0.000
Endoscopy Post intervention 0.022 0.008 0.037 0.003 0.023 0.009 0.038 0.002
Ontario 0.018 0.005 0.031 0.006 0.009 −0.004 0.022 0.182
Ontario*Post 0.007 −0.007 0.021 0.301 0.009 −0.005 0.023 0.207
N = 58,142; Weighted N = 2,882,630. All results are weighted.
Dependent variable is self-report of having a FOBT or endoscopy (flexible sigmoidoscopy or colonoscopy) in past year.
a: controlled for year and province indicators.
b: controlled for year, province, sex, age category, geography, self-rated health, having MD, reporting flu shot, physical activity index, smoking status, ethnicity,
education, income, #GP consultations past year.
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ommended to be administered more frequently than
other screening tests. On the other hand, screening rates
for colorectal cancer are much lower than for other can-
cers, so a priori it was not obvious whether the program
would succeed in overcoming evident barriers to screen-
ing and increase screening rates.
In contrast, recommendations for endoscopy in our
target group call for its use in screening at up to 10 year
intervals [9] and as a follow-up test to positive FOBT re-
sults. Length of time to follow-up with endoscopy and
low adherence for the procedure may account for our
lack of observed effect. Results from the Ontario Pilot
recorded median follow-up times from positive FOBT to
endoscopy of 121 days in men and 202 in women [40].
Preliminary program results measured follow-up endos-
copy within six months following a positive FOBT at
62.1% [23] with only 55% being performed within the
target eight weeks [41]. Supply constraints and signifi-












N = 58,142; Weighted N = 2,882,630. Except a: N = 98,023; Weighted N = 5,844,306.
Dependent variables are self-report of having a FOBT or endoscopy (flexible sigmoi
having a regular medical doctor, being aged 65–74 years, being aged 35–49 years,
ever having had a flu shot. Control variables include year, province, Group, Time, G
reporting flu shot, physical activity index, smoking status, ethnicity, education, inco
the characteristics listed above.other factors which could lead to delays. The time frame
of this study was therefore likely insufficient to capture a
potential increase in endoscopy use resulting from in-
creased FOBT screening. Additionally, low follow-up
may be explained by the fact that one third of FOB tests
performed in Ontario in 2009–10 were outside of the
ColonCancerCheck program and did not benefit from
the program’s registry and follow-up processes [43]. The
restrictions of the study period and the inability to assess
program-specific clinical outcomes are inherent con-
straints of the study, and offer important avenues for fu-
ture research.
We did not observe evidence of effect modification by
having a regular physician for FOBT screening in post-
intervention Ontario, which was somewhat surprising
given the central role of primary care providers in the
program [23]. One possible explanation is that outreach
to individuals without PCPs was improved through the
program. Secondary analyses [34] found similar in-
creases in screening amongst those with a regular doctorecal occult blood test and endoscopy outcomes
DDD
effect 95% CI p
8 −0.095 0.111 0.883
8 −0.008 0.065 0.127
20 −0.052 0.012 0.214
7 −0.029 0.042 0.720
0 −0.031 0.052 0.623
5 −0.007 0.137 0.077
2 −0.022 0.027 0.853
03 −0.027 0.022 0.835
07 −0.035 0.021 0.628
All results are weighted.
doscopy or colonoscopy) in past year. Group*Time terms are interacted with
self-report of “inactive” on the Leisure Physical Activity Index, and reporting
roup*Time, sex, age category, geography, self-rated health, having MD,
me, #GP consultations past year, and Group* and Time* interactions with all of
Table 5 Placebo test for incorrect policy implementation
period
Outcome DD
Marginal effect 95% CI p
FOBT Post interventiona 0.0875 0.0551 0.1200 0.000
Ontario 0.0688 0.0439 0.0936 0.000
Ontario*Posta −0.0204 −0.0557 0.0148 0.256
Endoscopy Post interventiona 0.0001 −0.0205 0.0208 0.989
Ontario 0.0100 −0.0052 0.0253 0.198
Ontario*Posta 0.0218 −0.0010 0.0447 0.061
N = 30,484; Weighted N = 1,468,619. All results are weighted. Dependent
variable is self-report of having a FOBT or endoscopy (flexible sigmoidoscopy
or colonoscopy) in the past year. Controlled for year, province, sex, age
category, geography, self-rated health, having MD, reporting flu shot, physical
activity index, smoking status, ethnicity, education, income, #GP consultations
past year.
a: The post intervention period has been altered to equal 2007. Data from
2008–9 are not included.
Table 6 Placebo test for alternate dependent variable
(Flu Shot)
Outcome DD
Marginal effect 95% CI p
Flu shot Post intervention 0.0743 0.0453 0.1032 0.000
Ontario 0.2588 0.2366 0.2810 0.000
Ontario*Post −0.0153 −0.0436 0.0131 0.291
N = 58,142; Weighted N = 2,882,630. All results are weighted. Dependent
variable is self-report of ever having a flu shot. Controlled for year, province,
sex, age category, geography, self-rated health, having MD, physical activity
index, smoking status, ethnicity, education, income, #GP consultations
past year.
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supports the idea of temporal, rather than program-
derived, influence of PCPs on patient screening.
There are several study limitations that should be ad-
dressed. First, because the colorectal cancer screening
module was not asked in all provinces in all survey
waves, we were required to use an unbalanced panel for
our control group. This may have disproportionately
represented Eastern Canada and biased screening trends
in the pre-intervention period downward. This is a con-
cern because, even though the DD and DDD designs
can control for time-invariant group differences, alter-
ation of the control group can distort trends and lead to
differential results. In particular, the year 2005 indicated
a decrease in proportion screened from the previous sur-
vey year from 8.34% to 7.03% for the FOBT outcome
which was uncharacteristic of the overall trend. How-
ever, Table 5 indicates that the DD model is robust to
unmeasured trends given the lack of an estimated effect
in the pseudo-treatment period.
A second concern is residual confounding based on
time-varying unmeasured factors in this observational
study. To address this concern, we examined several in-
teractions including having a regular doctor, being aged
65–74 years and 35–49 years, being “inactive”, and
reporting ever having had a flu shot. These were chosen
given their face validity and common citation in the lit-
erature as modifiers of screening. Given no evidence of
effect modification by these factors, and no sources of
bias found in any other verification test, it seems un-
likely that other confounders would bias our estimates
appreciably. Although past year outcomes were used to
reduce exposure misclassification, the retrospective na-
ture of the reporting likely results in some degree of
misclassification and potential attenuation of the treat-
ment effect. Underestimation of standard errors throughauto-correlated residuals is common to DD [44],
however the relatively short time series and independent
nature of the dependent variables mitigates this. Meas-
urement error in self-reported screening rates is another
concern, with FOBT recall accuracy estimated to have a
sensitivity of 82% and specificity of 78% [45]. Assuming
that potential reporting errors are similar in the treat-
ment and control groups given consistency in mode of
collection and phrasing of questions [35], we expect the
DD design to protect against the effects of these errors.
Finally, there is the possibility of reverse causality,
where previous conditions or legislation in Ontario
brought about the decision for policy change and inde-
pendently affected subsequent screening outcomes. We
believe that due to federal oversight establishing guar-
antees for reasonable access to care, harmonized train-
ing of healthcare professionals, and conditional transfer
payments from the federal government to provinces
[17], the concerns of heterogeneity of health services
delivery across provinces are dramatically reduced and
the likelihood of endogenous factors driving policy
change diminished. In Canada, the most severe dispar-
ities in health services delivery occur along north–south
lines [17] which is in partly why the three Canadian
territories were excluded from the analysis. Further-
more, that ColonCancerCheck utilizes previously estab-
lished national screening guidelines common to all of
Canada [7-9], and two other provinces in addition to
Ontario are adapting similar programs, further lessens
this concern.
Conclusions
Our use of a quasi-experimental approach to derive a
causal measure of the impact of the CRC screening
program ColonCancerCheck from CCHS microdata files
demonstrates the effectiveness of the program in
increasing past-year screening by FOBT up to the end
of 2009. The results from this study are largely
generalizable to other Canadian provinces [46] in
addition to other countries [47,48] which, in many cases,
have commonalities in target populations and screening
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cessful at increasing rates of screening with FOBT in the
asymptomatic average risk population, this study pro-
vides evidence that the educational, instructional, and
other outreach strategies adopted by the program have
been successful. At this point, we are unable to make
conclusions as to the effect of the program on use of en-
doscopy as it is unlikely for an appreciable effect to be
observed so soon after program initiation. Another im-
portant caveat to this conclusion is that jurisdictions
with varying pre-intervention screening levels may
experience different degrees of outcomes, so the
generalizability of the effect measure should be inter-
preted with caution. We cannot speculate on the long-
term effects of ColonCancerCheck given that it is
ongoing [23], that its ability to induce sustained patterns
of preventive screening is unknown, and that it must
accommodate updated screening recommendations [10].
Updated evidence of the protective effect of flexible sig-
moidoscopy [49] and the improved sensitivity of [50]
and test adherence to [51] fecal immunochemical tests is
encouraging. The conclusions of the current study sug-
gest that similar programs will be capable of promoting
these procedures in the average risk population. Among
the most important questions in the effectiveness of the
program is its ability to reduce morbidity and mortality
from CRC. This is not addressed by this study and pre-
sents an important avenue for future research examin-
ing mortality, costs, stages of cancer at detection and
other important outcomes. Given previous evidence of
the effectiveness of CRC screening program-like inter-
ventions in reducing CRC mortality [11] our results
provide some level of optimism that this aim will be-
come fulfilled.
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